Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer

[1]  S. Steele,et al.  The American Society of Colon and Rectal Surgeons, Clinical Practice Guidelines for the Management of Appendiceal Neoplasms. , 2019, Diseases of the colon and rectum.

[2]  B. El-Rayes,et al.  Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. , 2019, The oncologist.

[3]  J. Meyerhardt,et al.  Systemic chemotherapy and survival in patients with metastatic low‐grade appendiceal mucinous adenocarcinoma , 2019, Journal of surgical oncology.

[4]  Danning Huang,et al.  Analysis of the National Cancer Data Base (NCDB) on impact and trend of neoadjuvant chemotherapy in upper urinary tract urothelial cancer. , 2019, Journal of Clinical Oncology.

[5]  P. Philip,et al.  Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer , 2019, Clinical Cancer Research.

[6]  L. Wood,et al.  GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling. , 2018, Gastroenterology.

[7]  Justin K. Huang,et al.  Genomic Landscape of Appendiceal Neoplasms. , 2018, JCO precision oncology.

[8]  A. Renehan,et al.  Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma , 2018, Diseases of the colon and rectum.

[9]  M. Pocard,et al.  A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. , 2018, Journal of Clinical Oncology.

[10]  T. Bekaii-Saab,et al.  Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis , 2017, American journal of clinical oncology.

[11]  Jeffrey S. Morris,et al.  Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes , 2017, Clinical Cancer Research.

[12]  A. Lowy,et al.  Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care , 2017, PloS one.

[13]  S. Chandana,et al.  Appendiceal adenocarcinoma: Analysis of SEER database. , 2017 .

[14]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[15]  R. Feldman,et al.  Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy , 2017, American journal of clinical oncology.

[16]  Lisa M McShane,et al.  Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. , 2017, The Journal of molecular diagnostics : JMD.

[17]  S. Millis,et al.  Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. , 2017, Journal of gastrointestinal oncology.

[18]  L. Miller,et al.  Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. , 2016, Journal of the American College of Surgeons.

[19]  C. Compton,et al.  The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base , 2016, Cancer.

[20]  L. Sobin,et al.  A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process , 2016, The American journal of surgical pathology.

[21]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[22]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[23]  Tsuyoshi Saito,et al.  A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. , 2015, Pathology, research and practice.

[24]  Funda Meric-Bernstam,et al.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Aldape,et al.  Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours , 2014, British Journal of Cancer.

[26]  A. Benson,et al.  Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[27]  G. Pelosi,et al.  FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. , 2014, The oncologist.

[28]  J. Davison,et al.  GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. , 2014, Human pathology.

[29]  C. Amos,et al.  Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. , 2014, Clinical chemistry.

[30]  K. Frazer,et al.  Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin , 2014, Genome Medicine.

[31]  Jeffrey S. Morris,et al.  Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. , 2013, The oncologist.

[32]  C. Nieroda,et al.  Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[33]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[34]  M. Overman,et al.  Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix: The Prognostic Impact of Histological Grade , 2013, Annals of surgery.

[35]  T. Mori,et al.  Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms , 2013, British Journal of Cancer.

[36]  T. Chua,et al.  Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Hsu,et al.  Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. , 2012, Journal of the American College of Surgeons.

[38]  R. Wolff,et al.  Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  T. Bishop,et al.  Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix , 2011, Scandinavian journal of gastroenterology.

[40]  R. Wolff,et al.  Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin , 2010, Cancer.

[41]  A. Gökçimen,et al.  Development of the vermiform appendix during the fetal period , 2004, Surgical and Radiologic Anatomy.

[42]  S. Ashley,et al.  Appendiceal adenocarcinoma: Long-term outcomes after surgical therapy , 2004, Diseases of the colon and rectum.

[43]  N. Petrelli.  Commentary (Petrelli): Managing the Peritoneal Surface Component of Gastrointestinal Cancer , 2004 .

[44]  P. Sugarbaker.  Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. , 2004, Oncology.

[45]  Tsung-Teh Wu,et al.  Loss of chromosome 18q and DPC4 (Smad4) mutations in appendiceal adenocarcinomas , 2004, Oncogene.

[46]  Wareef Kabbani,et al.  Mucinous and Nonmucinous Appendiceal Adenocarcinomas: Different Clinicopathological Features but Similar Genetic Alterations , 2002, Modern Pathology.

[47]  Kathleen R. Cho,et al.  Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. , 1999, The American journal of pathology.

[48]  H. Chandler.  Data Base , 1985, Journal of learning disabilities.

[49]  D. Crivellari,et al.  A Single-Institution Experience , 2013 .

[50]  C. Greenberg,et al.  Understanding gaps in surgical quality: learning to count what cannot be counted. , 2013, Annals of surgery.

[51]  I. Drozdov,et al.  Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. , 2008, International journal of oncology.